This feature represents a relevant advantage in the perspective of a therapeutic approach, because, in clinical practice, it is frequent to combine different drugs to improve the effect on the target molecule. experimental approaches and was unequivocally proved by the discovery of oncogene is overexpressed in tumors of specific histotypes or is activated through autocrine mechanisms (for a VE-822 list see www.vai.org/vari/metandcancer). Besides, the gene is amplified in hematogenous metastases of colorectal carcinomas (11). Interfering with activation is, thus, becoming a challenging approach to hamper the tumorigenic and metastatic processes. In the past years, several strategies have been proposed to block aberrant HGFR signaling, targeting either the HGFR itself or its ligand. These approaches include the use of HGF antagonists, HGF neutralizing antibodies, HGFR decoys, ATP-binding-site inhibitors of HGFR, or small molecules, such as geldanamycin, SH2-domain polypeptides, and ribozymes (reviewed in ref. 12). Although many of these approaches are attractive, their clinical application still remains elusive, mainly due to problems in efficient delivery. In this work, we show that a monoclonal Ab directed against the extracellular domain of HGFR, is able to promote receptor down-regulation; the underlying molecular mechanism is different from that induced by ligand binding, and it involves proteolytic cleavage of the receptor, resulting in HGFR ectodomain release from the cell surface (shedding) and generation of the intracellular domain, which is rapidly degraded by the proteasome. As a consequence, Ab-induced receptor down-regulation impairs HGFR-activated signal transduction, abolishes the invasive growth response treatment of these cells with DN30 reduced the invasive properties in response to HGF. DN30 Inhibits the Transformed Phenotype female mice. The animals were treated twice a week with either DN30 or VSV-G, injected and and in the tumor twice a week with 2 g/g of either VSV-G or DN30. ( 0.05). (spontaneous metastasis (19). Tumor-bearing animals were treated twice a week with different doses of DN30 or the control mAb, administered either systemically (1 g/g or 10 g/g i.p.) or into the tumor (2 g/g (IS). As shown, DN30 inhibited tumor growth. (and and and and and and protooncogene is a RTK that, upon activation, elicits a complex spectrum of biological responses known as invasive growth, implying induction and coordination of cell proliferation, migration, differentiation, and survival. Under physiological conditions, this invasive growth program plays a pivotal role during embryo development, but, when unleashed in cancer, contributes to tumor progression and metastasis (33). The involvement of HGFR in human tumors is now firmly established, as germ-line missense mutations of the gene are responsible for some hereditary forms of cancer (9, 10), and inappropriate HGFR activation has been shown in most types of solid tumors, often correlating with poor prognosis (reviewed in ref. 34). The most frequent alteration in human cancers is receptor overexpression (33) that leads to constitutive dimerization and activation of the receptor, even in the absence of ligand (35). Increased HGFR expression can be due to (confers to neoplastic cells a selective advantage for liver metastasis (11); ((36C39); or (in human tumors VE-822 (34), our observations might have an impact for antineoplastic therapy. DN30-induced HGFR down-regulation leads VE-822 to inhibition of receptor-mediated signal transduction and, in particular, of the Akt pathway, known to be involved in the antiapoptotic response. This finding is consistent with our observations, because we have shown that treatment with DN30 resulted in impairment of anchorage-independent growth, a property that Rabbit Polyclonal to Stefin A requires the escape from apoptosis due to lack of anchorage. (32) obtained similar findings targeting HGFR by using a soluble receptor form (decoy Met) corresponding to the shed ectodomain produced upon Ab treatment. It is worth noting that treatment with DN30 did not impact the functionality of different organs such as spleen, bone marrow, liver, heart, bone, and kidney, which did not show evident pathological modifications (data not proven) after long-term contact with the Ab. To conclude, our results recommend Ab-induced down-regulation of HGFR as an applicant device for immunotherapy, because down-regulation of development factor receptors is known as a critical system of indication attenuation (46, 47). This type of Ab exploits its impact in inhibiting HGFR signaling with a dual system: Similarly it reduces the amount of receptor substances over the cell surface area; alternatively it promotes the discharge of the decoy HGFR which, regarding to our former (32) and present observations, is normally endowed using a prominent detrimental activity. Another essential observation would be that the inhibitory system activated with the Ab will not need HGFR tyrosine kinase activity. This feature represents another benefit in the perspective of the therapeutic strategy, because,.